Graft-versus-Host Disease

Acute Graft-versus-Host Disease (aGvHD) contributes significantly to morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Diagnosis of GvHD is mainly based on clinical features and tissue biopsies. Early detection of aGvHD is crucial to enable timely initiation of treatment.

Using capillary electrophoresis mass spectrometry (CE-MS), we established a urinary proteomic profile of 17 peptides allowing early and accurate diagnosis of patients developing severe aGvHD 14 days prior to any clinical signs with 82.4% sensitivity and 77.3% specificity. This study was published in the prestigious scientific journal Leukemia.

Our high-resolution urine proteome analysis represents the first unbiased non-invasive screening method for early and accurate diagnosis of severe aGvHD. Hence, it can serve as decision criterion for the initiation of preemptive steroid treatment before progression of aGvHD to a lethal stage.